BRPI0808353B8 - usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados - Google Patents

usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados

Info

Publication number
BRPI0808353B8
BRPI0808353B8 BRPI0808353A BRPI0808353A BRPI0808353B8 BR PI0808353 B8 BRPI0808353 B8 BR PI0808353B8 BR PI0808353 A BRPI0808353 A BR PI0808353A BR PI0808353 A BRPI0808353 A BR PI0808353A BR PI0808353 B8 BRPI0808353 B8 BR PI0808353B8
Authority
BR
Brazil
Prior art keywords
hydroxy
amino
propionic acid
acid amides
heteroaryl
Prior art date
Application number
BRPI0808353A
Other languages
English (en)
Inventor
J Schweighoffer Fabien
E Donello John
M Luhrs Lauren
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0808353A2 publication Critical patent/BRPI0808353A2/pt
Publication of BRPI0808353B1 publication Critical patent/BRPI0808353B1/pt
Publication of BRPI0808353B8 publication Critical patent/BRPI0808353B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados. a presente invenção refere-se a usos de compostos de fórmulas 1 e 2 fórmula 1 nas quais as variáveis têm os significados descritos na especificação, para a fabricação de medicamentos para o tratamento de um paciente que sofre de um distúrbio cognitivo.
BRPI0808353A 2007-03-06 2008-03-04 usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados BRPI0808353B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89319607P 2007-03-06 2007-03-06
US60/893,196 2007-03-06
PCT/US2008/055812 WO2008109610A1 (en) 2007-03-06 2008-03-04 Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds

Publications (3)

Publication Number Publication Date
BRPI0808353A2 BRPI0808353A2 (pt) 2014-07-29
BRPI0808353B1 BRPI0808353B1 (pt) 2020-03-31
BRPI0808353B8 true BRPI0808353B8 (pt) 2021-05-25

Family

ID=39535350

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808353A BRPI0808353B8 (pt) 2007-03-06 2008-03-04 usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados

Country Status (11)

Country Link
US (1) US8623891B2 (pt)
EP (2) EP2131837B1 (pt)
JP (1) JP2010520299A (pt)
AU (3) AU2008222890C1 (pt)
BR (1) BRPI0808353B8 (pt)
CA (1) CA2680324A1 (pt)
DK (1) DK2481407T3 (pt)
ES (2) ES2711075T3 (pt)
PT (1) PT2481407T (pt)
TR (1) TR201818771T4 (pt)
WO (1) WO2008109610A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL383715A1 (pl) * 2005-01-26 2008-05-12 Allergan, Inc. Amidy kwasu 3-arylo-3-hydroksy-2-amino-propionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-amino-propionowego i ich związki pokrewne posiadające aktywność przeciwbólową i/lub pobudzającą odporność
CA2693369A1 (en) * 2007-07-17 2009-01-22 Allergan, Inc. Methods for treating anxiety
EP2453890B1 (en) * 2009-07-17 2020-05-27 Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
BR112012006073A2 (pt) 2009-09-16 2016-05-31 Allergan Inc composições e métodos para tratar espasticidade.
EP2477623A1 (en) * 2009-09-16 2012-07-25 Allergan, Inc. Compositions and methods for treating disorders of gastrointestinal motility
JP2013505248A (ja) 2009-09-16 2013-02-14 アラーガン インコーポレイテッド 発作性疾患を治療するための組成物及び方法
CA2921385C (en) * 2013-08-15 2021-10-19 Allergan, Inc. (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62114946A (ja) 1985-11-13 1987-05-26 Banyu Pharmaceut Co Ltd フエニルセリンアミド誘導体およびそれを有効成分とする中枢神経系用剤
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
SE9904197D0 (sv) 1999-11-22 1999-11-22 Amersham Pharm Biotech Ab A method for anion exchange adsorption on matrices carrying mixed mode ligands
US6855830B2 (en) * 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US20050101674A1 (en) * 2003-11-12 2005-05-12 Maurer Barry J. PPMP as a ceramide catabolism inhibitor for cancer treatment
US20060081273A1 (en) * 2004-10-20 2006-04-20 Mcdermott Wayne T Dense fluid compositions and processes using same for article treatment and residue removal
PL383715A1 (pl) * 2005-01-26 2008-05-12 Allergan, Inc. Amidy kwasu 3-arylo-3-hydroksy-2-amino-propionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-amino-propionowego i ich związki pokrewne posiadające aktywność przeciwbólową i/lub pobudzającą odporność
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011485A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain

Also Published As

Publication number Publication date
ES2711075T3 (es) 2019-04-30
CA2680324A1 (en) 2008-09-12
EP2481407A1 (en) 2012-08-01
TR201818771T4 (tr) 2019-01-21
EP2481407B1 (en) 2018-09-26
EP2131837B1 (en) 2012-05-16
HK1139855A1 (en) 2010-09-30
ES2383384T3 (es) 2012-06-20
US8623891B2 (en) 2014-01-07
PT2481407T (pt) 2018-12-28
WO2008109610A1 (en) 2008-09-12
JP2010520299A (ja) 2010-06-10
AU2008222890A1 (en) 2008-09-12
BRPI0808353A2 (pt) 2014-07-29
US20100093793A1 (en) 2010-04-15
EP2131837A1 (en) 2009-12-16
AU2018204290B2 (en) 2020-05-21
AU2008222890B2 (en) 2016-03-31
AU2016204334A1 (en) 2016-07-14
AU2008222890C1 (en) 2016-09-08
AU2018204290A1 (en) 2018-07-05
DK2481407T3 (en) 2019-01-07
BRPI0808353B1 (pt) 2020-03-31
AU2016204334B2 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
ATE530524T1 (de) Substituierte sulfonamid-derivate
CR20130308A (es) Compuestos y su uso como inhibidores de bace
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BR112013008667A2 (pt) compostos substituídos de benzamida
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
CO6331434A2 (es) Nuevos compuestos
GT201400242A (es) "nuevos compuestos de pirazol"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF